FALCO HOLDINGS Co., Ltd (4671) AI Stock Analysis

• Market Cap: ¥25.05B
• Dividend Yield: 4.94%
• Average Volume (3M): 15.15K
• Price to Earnings (P/E): 13.2
• Beta (1Y): 0.60
• Revenue Growth: 1.01%
• EPS Growth: 13.91%
• Country: JP
• Employees: 1,117
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 31.65
• Shares Outstanding: 10,880,177
• 10 Day Avg. Volume: 15,890
• 30 Day Avg. Volume: 15,146
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥2,494.00
• Price Target Upside: -0.16% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 67 Neutral
• Price Target: ¥2,494.00 ▼(-0.16% Downside)

The overall stock score is driven by strong financial performance with a robust balance sheet and reasonable valuation metrics, including a high dividend yield. Technical indicators present a mixed picture with no clear bullish momentum. The absence of earnings call details and corporate events means these factors do not influence the score.

FALCO HOLDINGS Co., Ltd Business Overview & Revenue Model

Company Description

FALCO HOLDINGS Co., Ltd (4671) is a Japan-based company primarily engaged in the provision of clinical testing and healthcare-related services. The company operates through various segments, including clinical testing, pharmaceuticals, and environmental testing services. It offers a wide range of services such as blood testing, pathological diagnostics, and other laboratory testing services essential for healthcare professionals and institutions.

How the Company Makes Money

FALCO HOLDINGS Co., Ltd generates revenue mainly through its clinical testing services, which are provided to hospitals, clinics, and other healthcare facilities. These services include routine blood tests, specialized diagnostic testing, and pathological examinations. The company also earns income from its pharmaceutical segment by distributing prescription medications and healthcare products. Additionally, FALCO HOLDINGS provides environmental testing services, contributing to its revenue by offering analytical and inspection services to ensure environmental compliance and safety. Key partnerships with healthcare providers and institutions enhance its market presence and drive sales growth.

FALCO HOLDINGS Co., Ltd Financial Statement Overview

Summary

FALCO HOLDINGS Co., Ltd demonstrates stable financial health with strong balance sheet metrics and reasonable profitability. Despite a declining revenue trend, the company benefits from solid margins and low debt levels. Cash flow management is adequate but shows room for improvement in free cash flow generation. Overall, the company is well-positioned financially, with strengths in balance sheet stability and profitability, offset by challenges in revenue growth and cash flow efficiency.

Income Statement

The company showcases stable income statement metrics with a modest Gross Profit Margin averaging around 30.8% in the latest year. Net Profit Margin improved to 4.4% from the previous year, indicating better cost management. However, the revenue growth rate has been negative, reflecting a decline from the peak in 2022. The EBIT and EBITDA margins are consistent but show a downward trend from prior years.

Balance Sheet

The balance sheet remains solid with a low Debt-to-Equity Ratio of 0.06, indicating low leverage and financial risk. Return on Equity (ROE) stands at 7.6%, showing moderate profitability. The Equity Ratio is high at 70.1%, indicating strong solvency and financial stability. Overall, the company maintains a robust equity base with manageable liabilities.

Cash Flow

The cash flow statement reveals a decline in Free Cash Flow Growth Rate, with the latest year showing a decrease. Operating Cash Flow to Net Income Ratio remains healthy at 1.4, showcasing efficient cash generation relative to profits. However, Free Cash Flow to Net Income Ratio is 0.8, suggesting potential for improvement in cash retention.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	43.31B	43.31B	43.01B	46.91B	50.01B	43.61B
Gross Profit	13.35B	13.35B	12.92B	14.64B	17.32B	13.70B
EBITDA	3.72B	3.72B	3.56B	4.75B	6.55B	3.88B
Net Income	1.92B	1.92B	1.67B	2.26B	3.53B	1.85B
Balance Sheet
Total Assets	36.02B	36.02B	36.42B	38.89B	40.26B	37.07B
Cash, Cash Equivalents and Short-Term Investments	9.42B	9.42B	10.06B	12.60B	10.64B	11.62B
Total Debt	1.44B	1.44B	817.00M	2.80B	4.07B	5.90B
Total Liabilities	10.76B	10.76B	10.40B	12.30B	16.78B	16.59B
Stockholders Equity	25.25B	25.25B	26.03B	26.59B	23.48B	20.48B
Cash Flow
Free Cash Flow	0.00	1.54B	2.19B	708.00M	1.94B	1.32B
Operating Cash Flow	0.00	2.62B	3.43B	2.09B	4.13B	2.94B
Investing Cash Flow	0.00	-1.18B	-1.45B	322.00M	-2.69B	-52.00M
Financing Cash Flow	0.00	-2.08B	-4.53B	-448.00M	-2.41B	1.46B

FALCO HOLDINGS Co., Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2498.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4671, the sentiment is Positive. The current price of 2498 is above the 20-day moving average (MA) of 2462.60, above the 50-day MA of 2363.48, and above the 200-day MA of 2308.73, indicating a bullish trend. The MACD of 32.69 indicates Positive momentum. The RSI at 63.69 is Neutral, neither overbought nor oversold. The STOCH value of 71.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4671.

FALCO HOLDINGS Co., Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4671	67 Neutral	¥25.05B	13.18		4.94%	1.01%	13.91%
Sector *	51 Neutral	$7.85B	-0.18	-40.01%	2.28%	22.97%	-2.05%
BMZ	―	€802.40M	20.01	5.29%	―	―	―
MRCHF	―	$1.42B	167.36	0.95%	4.15%	―	―
2395	75 Outperform	¥69.36B	13.49		2.97%	27.28%	18.29%
9776	74 Outperform	¥3.68B	7.40		2.17%	2.23%	12.02%
3154	60 Neutral	¥18.52B	13.45		2.42%	11.12%	20.54%